HLS Therapeutics Inc.
HLS
Pozycja w akcjach
#21941
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Cena akcji
$3.01
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$92.97M
Zmiana (1 dzień)
0.86%
Zmiana (1 rok)
-25.24%
Kraj
CA
Handel HLS Therapeutics Inc. (HLS)
Kategoria
Healthcare
Wskaźnik P/S dla HLS Therapeutics Inc. (HLS)
Wskaźnik P/S na dzień 2026 TTM: 0
Według najnowszych raportów finansowych i ceny akcji HLS Therapeutics Inc., obecny wskaźnik P/S (TTM) wynosi 0. Na koniec 2026 wynosił 0.
Historia wskaźnika P/S dla HLS Therapeutics Inc. od 2026 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | - |
IN
|
